Cannabis Regulators Group Warns DEA Rescheduling Plan Strains State Supply
Cannabis Regulators Association executive Gillian Schauer says DEA's late-October medical marijuana actions leave states, patients and operators without a workable path.

US Department of Agriculture building with Washington Monument behind, blue sky with clouds.
Regulators' group says DEA's three late-October actions create a split-market problem
The Cannabis Regulators Association, which represents state cannabis regulators, says DEA's recent moves on federal medical marijuana rescheduling leave states guessing about how to structure their programs.
Gillian L. Schauer wrote the op-ed, published Nov. 16 by Marijuana Moment. She said that late last month the Drug Enforcement Administration took three significant actions related to federal medical marijuana rescheduling, beginning with the issuance of guidance. The op-ed's central warning is about capacity. In her words, supply chains in many states won't have enough cultivators, manufacturers and dispensaries to support a viable supply chain in either the DEA market or the state-only market.
That's a regulator's alarm, not an operator's complaint.
A two-track market is the structural problem
If DEA-registered activity runs alongside state-only activity, a single state's finite pool of licensees has to be divided between two regulatory regimes.
Most state programs were built around one licensed supply chain: cultivation, processing, retail. Layer a federal medical channel on top and you don't automatically get more producers. You ask the same ones to choose, or to split output across two compliance systems with different rules on testing, tracking, labeling and record-keeping.
On a strict reading of Schauer's argument, the shortfall is arithmetic. A state with a few dozen licensed cultivators can't staff two full supply chains. Thin markets in smaller states are the most exposed, and patients there are the ones who could lose reliable access.
Why the tax and compliance picture gets harder, not easier
Rescheduling to Schedule III would not by itself resolve the tax and licensing questions operators care about most.
Under IRC §280E, businesses trafficking in Schedule I or II substances can't deduct ordinary business expenses beyond cost of goods sold. Operators have pushed for rescheduling largely to escape that burden. But a divided market complicates things. Whether a given operator's activity falls inside or outside a federally recognized medical channel could determine which tax treatment applies, and the signal material doesn't say how DEA's guidance addresses that line.
That gap matters. Operators can't model effective tax rates, or decide which market to serve, without knowing which side of the line their revenue falls on.
States are being asked to plan without a finished federal framework
Regulators have to make licensing, inventory and enforcement decisions while the federal rules they'd be coordinating with remain unsettled.
Schauer's piece frames the issue as one of uncertainty for three groups: regulators, patients and market operators. State agencies write rules, set license caps and manage seed-to-sale tracking on timelines measured in months, so a federal pathway that shifts underneath them forces expensive rewrites or, worse, rules that conflict with federal requirements once those firm up.
In the association's telling, the core risk is that states could end up with neither a functioning federal-facing market nor a healthy state-only one.
Patients bear the downside if supply thins
The people most exposed to a fractured supply chain are medical patients who depend on consistent product availability.
If operators exit one market to concentrate on the other, product variety and availability can narrow. Patients in lower-population states, where licensee counts are already small, would feel it first. Regulators in those states face a hard tradeoff: tighten oversight to protect patients, or loosen it to keep enough operators in business.
Not an easy call.
What operators and investors should do with an op-ed
This is an advocacy piece from a regulator-aligned group, not a rule, and operators should read it as a signal of where state agencies are headed.
The signal material available for this story is limited to the op-ed's excerpt and framing. It doesn't reproduce the full text of DEA's three actions, so the specifics of the guidance remain outside what CannIntel can verify here. Operators should pull the primary DEA documents before making capital decisions. Still, the direction is clear. The people who license and inspect these businesses are telling Washington the current approach doesn't pencil out at the state level, which is a notable thing for a regulators' association to say publicly. For background on the federal process, see the CannIntel topic hub on DEA rescheduling.
The signals to track next
Watch for state agency responses, any DEA clarification on registration and tax treatment, and whether other regulators echo the supply-capacity concern.
Agencies in California, Colorado and Ohio will shape how the rest of the country reads the guidance, given the size of their markets and their regulatory bandwidth. If major states publicly adopt the Cannabis Regulators Association's capacity framing, DEA will face pressure to revise. If they stay quiet, the split-market scenario becomes the default planning assumption.
The next tell: whether DEA responds to state regulators' concerns before operators have to commit capital to one track or the other.
For complete background, history, and our ongoing coverage of this story:
Open the CannIntel topic hub →Frequently asked questions
Who wrote the op-ed on DEA's rescheduling approach?
Gillian L. Schauer of the Cannabis Regulators Association wrote the op-ed, published Nov. 16, 2026 by Marijuana Moment. It addresses DEA actions taken in late October on federal medical marijuana rescheduling.
What is the main concern raised about supply chains?
Schauer said many states won't have enough cultivators, manufacturers and dispensaries to support a viable supply chain in either a DEA market or a state-only market, because licensed operators would be split between two systems.
What did DEA do in late October?
According to the op-ed, DEA took three significant actions related to federal medical marijuana rescheduling, beginning with the issuance of guidance. The available signal excerpt doesn't detail the other two actions.
Does rescheduling end the §280E tax burden?
Not automatically. IRC §280E bars deductions for trafficking in Schedule I or II substances. Whether operators in a split medical-and-state market would escape it depends on how DEA's framework defines covered activity, which the signal doesn't specify.
Sources
The cannabis newsletter you forward to your team.
Federal policy, market data, grower alerts, and the one story that matters today. Sent every weekday at 7am. Free.
No spam. Unsubscribe with one click. 21+ only.
Related from Laws

Op-Ed Flags DEA Rescheduling Process as Source of Market Uncertainty
A Marijuana Moment op-ed argues DEA's handling of marijuana rescheduling has left state regulators, patients and licensed operators without a clear legal roadmap.

Wisconsin Democrat Says Legalization 'Definitely' Coming; GOP Leader Open
A top Wisconsin Senate Democrat predicted legalization next year while a Republican leader said he is open to discussing the issue, according to Marijuana Moment.

Pa. Senate Democrat Says Legalization Not 'High Priority' for 2027
A top Senate Democrat reportedly signaled that adult-use cannabis legalization is not a priority next year, leaving Pennsylvania's tax and licensing framework unwritten.
More from the newsroom

Testing Rules and Margin Pressure Dominate Cannabis Week of Nov. 9–15
A weekly roundup flags lab-testing rules and squeezed margins as the two forces shaping operator decisions, with import-dependent markets watching closely.

Trulieve Files to Open Medical Cannabis Dispensary in Tampa
The Florida MSO is adding another Tampa storefront to its home-market footprint, a bet that medical-only retail still pays in a state with no adult-use sales.

Schumer, Van Hollen Cannabis Records Come Under Scrutiny in Leadership Bid
A Marijuana Moment report maps where the two Senate Democratic leadership contenders stand on cannabis reform, a record that could shape floor time for SAFER Banking and descheduling.